These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15153080)

  • 1. Impact of inadequately controlled asthma: a need for targeted therapy?
    Mehlhop PD; Blake K
    J Clin Pharm Ther; 2004 Jun; 29(3):189-94. PubMed ID: 15153080
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and economic effects of suboptimally controlled asthma.
    Bootman JL; Crown WH; Luskin AT
    Manag Care Interface; 2004 Jan; 17(1):31-6. PubMed ID: 15035598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet need in inadequately controlled asthma.
    Beasley R
    Respirology; 2007 Nov; 12 Suppl 3():S18-21; discussion S45-7. PubMed ID: 17956515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IgE in severe persistent allergic asthma.
    Fox H
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
    Peters SP; Ferguson G; Deniz Y; Reisner C
    Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pratical aspects of anti-Ige therapy in severe allergic asthma].
    Taramarcaz P; Hauser C; Rochat T
    Rev Med Suisse; 2007 Apr; 3(108):1050-2, 1054-5. PubMed ID: 17552257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma in pediatric patients: unmet need and therapeutic options.
    Maykut R; Zeiger RS; Brown MA
    Clin Pediatr (Phila); 2010 Oct; 49(10):915-30. PubMed ID: 20724341
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Badly controlled severe persistent asthma: an additional new treatment].
    Nomémie L; Verpilleux MP; Ballouard K
    Soins; 2006 Dec; (711):19-21. PubMed ID: 17274408
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine].
    Nolte H; Harving H; Backer V
    Ugeskr Laeger; 2007 Dec; 169(50):4366-7. PubMed ID: 18211797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
    Liebhaber M; Dyer Z
    J Asthma; 2007 Apr; 44(3):195-6. PubMed ID: 17454337
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma 2008: targeting immunoglobulin E to achieve disease control.
    Prenner BM
    J Asthma; 2008 Aug; 45(6):429-36. PubMed ID: 18612893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The future of asthma therapy].
    Solèr M
    Schweiz Med Wochenschr; 2000 Feb; 130(8):277-81. PubMed ID: 10726286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of omalizumab in a severe asthma clinic.
    Gibson PG; Taramarcaz P; McDonald VM
    Respirology; 2007 Nov; 12 Suppl 3():S35-44; discussion S45-7. PubMed ID: 17956518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.